symbol,statement_type,period_end,line_item,value
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Tax Effect Of Unusual Items,529021517.438303
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Tax Rate For Calcs,0.147155
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Normalized EBITDA,12300000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Total Unusual Items,3595000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Total Unusual Items Excluding Goodwill,3595000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,8394000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Reconciled Depreciation,3686000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Reconciled Cost Of Revenue,23170000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,EBITDA,15895000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,EBIT,12209000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Net Interest Income,-2403000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Interest Expense,2403000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Interest Income,
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Normalized Income,5328021517.438303
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,8394000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Total Expenses,63870000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Rent Expense Supplemental,
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Diluted Average Shares,158826868.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Basic Average Shares,158407247.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Diluted EPS,52.85
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Basic EPS,52.99
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Diluted NI Availto Com Stockholders,8394000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Net Income Common Stockholders,8394000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Net Income,8394000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Minority Interests,31000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Net Income Including Noncontrolling Interests,8363000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Net Income Discontinuous Operations,
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Net Income Continuous Operations,8363000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Tax Provision,1443000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Pretax Income,9806000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Other Non Operating Income Expenses,568000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Special Income Charges,3595000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Other Special Charges,-4752000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Write Off,241000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Restructuring And Mergern Acquisition,916000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Net Non Operating Interest Income Expense,-2403000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Total Other Finance Cost,
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Interest Expense Non Operating,2403000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Interest Income Non Operating,
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Operating Income,8051000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Operating Expense,40700000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Other Operating Expenses,14759000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Depreciation And Amortization In Income Statement,3686000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Amortization,
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Depreciation Income Statement,3686000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Selling General And Administration,
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Selling And Marketing Expense,
JUBLPHARMA.NS,income,2025-03-31 00:00:00,General And Administrative Expense,
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Rent And Landing Fees,
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Gross Profit,48751000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Cost Of Revenue,23170000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Total Revenue,71921000000.0
JUBLPHARMA.NS,income,2025-03-31 00:00:00,Operating Revenue,71921000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Tax Effect Of Unusual Items,-506700000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Tax Rate For Calcs,0.3
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Normalized EBITDA,9936000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Total Unusual Items,-1689000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Total Unusual Items Excluding Goodwill,-1689000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,771000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Reconciled Depreciation,3819000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Reconciled Cost Of Revenue,21407000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,EBITDA,8247000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,EBIT,4428000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Net Interest Income,-2723000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Interest Expense,2723000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Interest Income,261000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Normalized Income,1953300000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,771000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Total Expenses,61259000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Rent Expense Supplemental,49000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Diluted Average Shares,158641975.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Basic Average Shares,158316222.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Diluted EPS,4.86
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Basic EPS,4.87
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Diluted NI Availto Com Stockholders,771000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Net Income Common Stockholders,771000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Net Income,771000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Minority Interests,44000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Net Income Including Noncontrolling Interests,727000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Net Income Discontinuous Operations,
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Net Income Continuous Operations,727000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Tax Provision,978000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Pretax Income,1705000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Other Non Operating Income Expenses,687000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Special Income Charges,-1689000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Other Special Charges,1689000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Write Off,
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Restructuring And Mergern Acquisition,
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Net Non Operating Interest Income Expense,-2723000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Total Other Finance Cost,159000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Interest Expense Non Operating,2723000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Interest Income Non Operating,261000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Operating Income,5189000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Operating Expense,39852000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Other Operating Expenses,14454000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Depreciation And Amortization In Income Statement,3819000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Amortization,521000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Depreciation Income Statement,3819000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Selling General And Administration,4406000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Selling And Marketing Expense,2143000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,General And Administrative Expense,2263000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Rent And Landing Fees,49000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Gross Profit,45041000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Cost Of Revenue,21407000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Total Revenue,66448000000.0
JUBLPHARMA.NS,income,2024-03-31 00:00:00,Operating Revenue,66448000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Tax Effect Of Unusual Items,-193500000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Tax Rate For Calcs,0.3
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Normalized EBITDA,8149000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Total Unusual Items,-645000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Total Unusual Items Excluding Goodwill,-645000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,-610000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Reconciled Depreciation,5540000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Reconciled Cost Of Revenue,22228000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,EBITDA,7504000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,EBIT,1964000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Net Interest Income,-1784000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Interest Expense,1686000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Interest Income,98000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Normalized Income,-158500000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,-610000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Total Expenses,59894000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Rent Expense Supplemental,78000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Diluted Average Shares,159147533.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Basic Average Shares,159147533.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Diluted EPS,-3.83
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Basic EPS,-3.83
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Diluted NI Availto Com Stockholders,-610000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Net Income Common Stockholders,-610000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Net Income,-610000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Minority Interests,39000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Net Income Including Noncontrolling Interests,-649000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Net Income Discontinuous Operations,
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Net Income Continuous Operations,-649000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Tax Provision,927000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Pretax Income,278000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Other Non Operating Income Expenses,113000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Special Income Charges,-595000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Other Special Charges,595000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Write Off,
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Restructuring And Mergern Acquisition,
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Net Non Operating Interest Income Expense,-1784000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Total Other Finance Cost,196000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Interest Expense Non Operating,1686000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Interest Income Non Operating,98000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Operating Income,2299000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Operating Expense,37666000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Other Operating Expenses,6800000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Depreciation And Amortization In Income Statement,5540000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Amortization,2379000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Depreciation Income Statement,3161000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Selling General And Administration,3847000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Selling And Marketing Expense,1616000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,General And Administrative Expense,2231000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Rent And Landing Fees,78000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Gross Profit,39965000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Cost Of Revenue,22228000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Total Revenue,62193000000.0
JUBLPHARMA.NS,income,2023-03-31 00:00:00,Operating Revenue,62193000000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Tax Effect Of Unusual Items,-11115607.06927
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Tax Rate For Calcs,0.344884
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Normalized EBITDA,11536150000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Total Unusual Items,-32230000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Total Unusual Items Excluding Goodwill,-32230000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,4139360000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Reconciled Depreciation,3817040000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Reconciled Cost Of Revenue,17869880000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,EBITDA,11503920000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,EBIT,7686880000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Net Interest Income,-1430350000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Interest Expense,1382410000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Interest Income,24510000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Normalized Income,4160474392.93073
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,4139360000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Total Expenses,52347140000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Rent Expense Supplemental,44950000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Diluted Average Shares,159173999.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Basic Average Shares,159173999.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Diluted EPS,26.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Basic EPS,26.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Diluted NI Availto Com Stockholders,4139360000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Net Income Common Stockholders,4139360000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Otherunder Preferred Stock Dividend,0.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Net Income,4139360000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Minority Interests,9200000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Net Income Including Noncontrolling Interests,4130160000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Net Income Discontinuous Operations,0.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Net Income Continuous Operations,4130160000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Tax Provision,2174310000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Pretax Income,6304470000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Other Non Operating Income Expenses,86900000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Special Income Charges,-33700000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Other Special Charges,33700000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Write Off,
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Restructuring And Mergern Acquisition,
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Net Non Operating Interest Income Expense,-1430350000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Total Other Finance Cost,72450000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Interest Expense Non Operating,1382410000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Interest Income Non Operating,24510000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Operating Income,8244510000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Operating Expense,34477260000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Other Operating Expenses,6097100000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Depreciation And Amortization In Income Statement,3817040000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Amortization,895470000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Depreciation Income Statement,2921570000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Selling General And Administration,4555090000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Selling And Marketing Expense,2097130000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,General And Administrative Expense,2457960000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Rent And Landing Fees,44950000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Gross Profit,42721770000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Cost Of Revenue,17869880000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Total Revenue,60591650000.0
JUBLPHARMA.NS,income,2022-03-31 00:00:00,Operating Revenue,60591650000.0
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Tax Effect Of Unusual Items,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Tax Rate For Calcs,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Normalized EBITDA,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Total Unusual Items,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Total Unusual Items Excluding Goodwill,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Net Income From Continuing Operation Net Minority Interest,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Reconciled Depreciation,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Reconciled Cost Of Revenue,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,EBITDA,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,EBIT,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Net Interest Income,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Interest Expense,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Interest Income,80970000.0
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Normalized Income,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Net Income From Continuing And Discontinued Operation,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Total Expenses,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Rent Expense Supplemental,49080000.0
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Diluted Average Shares,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Basic Average Shares,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Diluted EPS,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Basic EPS,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Diluted NI Availto Com Stockholders,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Net Income Common Stockholders,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Otherunder Preferred Stock Dividend,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Net Income,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Minority Interests,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Net Income Including Noncontrolling Interests,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Net Income Discontinuous Operations,2617530000.0
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Net Income Continuous Operations,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Tax Provision,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Pretax Income,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Other Non Operating Income Expenses,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Special Income Charges,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Other Special Charges,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Write Off,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Restructuring And Mergern Acquisition,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Net Non Operating Interest Income Expense,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Total Other Finance Cost,107400000.0
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Interest Expense Non Operating,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Interest Income Non Operating,80970000.0
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Operating Income,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Operating Expense,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Other Operating Expenses,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Depreciation And Amortization In Income Statement,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Amortization,884970000.0
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Depreciation Income Statement,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Selling General And Administration,4094060000.0
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Selling And Marketing Expense,1771460000.0
JUBLPHARMA.NS,income,2021-03-31 00:00:00,General And Administrative Expense,2322600000.0
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Rent And Landing Fees,49080000.0
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Gross Profit,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Cost Of Revenue,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Total Revenue,
JUBLPHARMA.NS,income,2021-03-31 00:00:00,Operating Revenue,
